Genetic data held by Genomics England is “incredibly valuable” for pharmaceutical companies, and has been leveraged to help clinical trial sponsors optimize their regulatory submissions and trial protocols as well as identify new targets and biomarkers, says IQVIA’s head of genomic and precision medicine Ricarda Gaentzsch.
“Because of this vast amount of genomic data, whole genome sequencing data and the link to clinical data, you can look at biomarker certification for treatment patterns and outcomes for...